CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
Key Highlights: Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to...
Ping An Rewarded MSCI AAA ESG Rating, Setting the Insurance Industry Benchmark in Asia-Pacific for Four Year Running
HONG KONG and SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or "the Group", HKEX: 2318/82318; SSE: 601318) has been upgraded to the highest global ESG rating of AAA for 2025 by MSCI, a leading...